The advent of PSMA-targeted imaging agents, particularly Gallium-68-labeled tracers (68Ga-PSMA), has revolutionized prostate cancer diagnostics, first gaining traction in Europe about a decade ago [5]. Here, FOLH1 is linked to prostate carcinoma.